Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07456306

Artificial Intelligence-Driven Virtual Reality Rehabilitation for Upper Limb Recovery in Acute and Subacute Stroke Patients

Background: Upper limb motor deficits are common after stroke, and early rehabilitation is crucial for functional recovery. Virtual reality (VR) combined with artificial intelligence (AI) has shown potential to enhance motor learning, but evidence from randomized controlled trials in acute and subacute hospitalized patients is limited.

Objective: To evaluate whether AI-driven VR rehabilitation in addition to standard care improves upper limb motor recovery compared with standard rehabilitation alone in acute and subacute stroke patients.

Design: Prospective, assessor-blinded, randomized controlled trial with stratified 1:1 allocation by baseline Fulg Meyer Assessment Score.S Participants: Adults (≥18 years) with confirmed acute or subacute stroke, admitted to the hospital, with upper limb motor déficits.

Intervention: Experimental group will receive standard rehabilitation plus AI-driven VR therapy during hospitalization. Control group will receive standard rehabilitation alone.

Primary Outcome: Change in FM-UE score from baseline to hospital discharge. Secondary Outcomes: VR-derived digital biomarkers, therapy adherence, NIHSS, FM-UE, and Modified Ashworth Scale at each session, and the following baseline and treatment variables: etiology, Modified Rankin Scale (mRS), handedness, stroke lateralization, aphasia, acute reperfusion, reperfusion treatment, days from stroke to start of rehabilitation, adverse events, patient satisfaction, and date of discharge. FM-UE at 1 month post-intervention.

Randomization and Blinding: Patients will be randomized in a 1:1 ratio to either group, stratified by baseline FM-UE (≤30 vs >30) to ensure balance between groups for stroke severity. Within each stratum, block randomization will be used. Outcome assessors will be blinded.

Sample Size: 50 patients (25 per group).

Ethics and Registration: Approved by hospital ethics committee. Significance: This trial will provide evidence on the effectiveness of AI-driven VR therapy for early upper limb rehabilitation in hospitalized stroke patients.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults ≥18 years
  • Confirmed acute or subacute stroke (ischemic or hemorrhagic)
  • Upper limb motor deficits
  • Admitted to hospital
  • Favourable assessment by the rehabilitation service to begin treatment
  • Signing of informes consent

Exclusion criteria

  • Moderate to severe cognitive impairment.
  • Severe global aphasia.
  • Language barrier.
  • Visual impairment.
  • Previous stroke with significant sequelae in upper limb.
  • Contraindication for RHB therapy.

Treatment and study plan

AI-driven VR rehabilitation therapy

Device

AI-drive VR device which improves rehabilitation of upper limb impairment

Standard rehabilitation

Device

Standard rehabilitation followed by rehabilitation team and physicians

Primary outcomes

  1. Motor function

    Time frame: Through study completion, an average of 3 months

    Fugl-Meyer Assessment

Secondary outcomes

  1. Neurological sequelae

    Time frame: Through study completion, an average of 3 months

    NIH Stroke Scale (NIHSS)

  2. Dependence in daily activities

    Time frame: Through study completion, an average of 3 months

    Modified Rankin Scale (mRS)

  3. Spasticity

    Time frame: Through study completion, an average of 3 months

    Modified Ashworth Scale (MAS)

  4. Muscle strenght

    Time frame: Through study completion, an average of 3 months

    Medical Research Council (MRC) scale

  5. Digital biomarkers from VR sessions

    Time frame: Through study completion, an average of 3 months

    Velocity and accurance of the movements

  6. Patient satisfaction

    Time frame: Through study completion, an average of 3 months

    Patient self-reporting

  7. Therapy adherence

    Time frame: Through study completion, an average of 3 months

    Patient self-reporting,

Other outcomes

  1. Age

    Time frame: Through study completion, an average of 3 months

    Years from birth

  2. Gender

    Time frame: Through study completion, an average of 3 months

    Sex

  3. Ethiology of the stroke

    Time frame: Through study completion, an average of 3 months

    TOAST clasification

  4. Dominant-hemisphere

    Time frame: Through study completion, an average of 3 months

    Handedness

  5. Stroke topography

    Time frame: Through study completion, an average of 3 months

    Clinical exploration

  6. Aphasia

    Time frame: Through study completion, an average of 3 months

    Clinical Exploration

  7. Pre-stroke disability

    Time frame: Through study completion, an average of 3 months

    Rankin scale pre-stroke

  8. Reperfusion treatment

    Time frame: Through study completion, an average of 3 months

  9. Time till the start of rehabilitation therapy

    Time frame: Through study completion, an average of 3 months

    Days

  10. Total of VR-sessions

    Time frame: Through study completion, an average of 3 months

    Number

Study contacts

Contact information is provided by the study sponsor or research team.

Beatriz Villarrubia González Villarrubia, MSc, MD, Dr.

CONTACT

[email protected]

+34 689189775

Sponsors and collaborators

Lead sponsor

Complejo Asistencial Universitario de León Urgencias

Other

Collaborators

  • University of Salamanca

Registry information

Official study title

Randomized Controlled Trial of Artificial Intelligence-Driven Virtual Reality Rehabilitation for Upper Limb Recovery in Acute and Subacute Stroke Patients

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Mar 6, 2026
Registry last updated
Mar 6, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.